logo

For the Inventor, By the Inventor

Deerfield, IL, United States of America

Takeda Pharmaceuticals U.s.a., Inc.

USPTO Granted Patents = 24

% Expired Patents = 20.8



Trademarks = 34

Forward Citations = 82

Loading Chart...
Loading Chart...

34 inventors (with patents filed for the assignee):

goldMedal Rajneesh Taneja (5 out of 8 patents)

silverMedal Majid Vakilynejad (5 out of 5 patents)

bronzeMedal Matthew William Davis (5 out of 21 patents)

4.  Ronald D Lee (3 out of 3 patents)

5.  Tong Sun (3 out of 6 patents)

6.  Vijay Gupte (2 out of 2 patents)

7.  Shawn Watson (2 out of 4 patents)

8.  Lhanoo Gunawardhana (2 out of 2 patents)

9.  Max Tsai (2 out of 2 patents)

10.  Himanshu Naik (2 out of 2 patents)

11.  Hengsheng Feng (2 out of 6 patents)

12.  Brian R Bettencourt (2 out of 2 patents)

13.  Nessan Anthony Bermingham (2 out of 2 patents)

14.  Robert B Dubridge (1 out of 49 patents)

15.  Anand Panchal (1 out of 6 patents)


24 patents:

1. 12485136 - Methods for the treatment of trinucleotide repeat expansion disorders associated with MLH3 activity (2025-12-02),
2. 12478673 - CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINS (2025-11-25),
3. 12297432 - Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity (2025-05-13),
4. 9937157 - Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors (2018-04-10),
5. 9889152 - Multiple PPI dosage form (2018-02-13),
6. 9889125 - Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy (2018-02-13),
7. 9255063 - Colchicine solid-state forms; methods of making; and methods of use thereof (2016-02-09),
8. 9248119 - Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors (2016-02-02),
9. 9238029 - Multiple PPI dosage form (2016-01-19),
10. 9233103 - Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy (2016-01-12),
11. 9107912 - Methods for concomitant treatment of theophylline and febuxostat (2015-08-18),
12. 8841333 - Methods for treating nephrolithiasis (2014-09-23),
13. 8785491 - Pharmaceutical compositions and methods for treating age-related macular degeneration with melatonin analogues (2014-07-22),
14. 8519002 - Colchicine solid complex; methods of making; and methods of use thereof (2013-08-27),
15. 8497290 - Thiocolchicine derivatives, method of making and methods of use thereof (2013-07-30),
Company Overview
Takeda Pharmaceuticals U.S.A., Inc., headquartered in Deerfield, Illinois, is a leading global biopharmaceutical company focused on developing innovative medicines for patients with complex diseases. The organization specializes in areas such as oncology, gastroenterology, neuroscience, and rare diseases, leveraging advanced research and technology to address unmet medical needs. With a commitment to patient-centric solutions, Takeda aims to enhance the quality of life for individuals worldwide through its diverse portfolio of therapeutic offerings.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#16 in Deerfield, IL

#722 in Illinois

#13,895 in US

#26,686 in the World

Deerfield, IL (US)
Deerfield, IL, United States of America

Takeda Pharmaceuticals U.s.a., Inc.

Forward Citations = 82

34 inventors:

goldMedal Rajneesh Taneja (5 out of 8 patents)

silverMedal Majid Vakilynejad (5 out of 5 patents)

bronzeMedal Matthew William Davis (5 out of 21 patents)

4.  Ronald D Lee (3 out of 3 patents)

5.  Tong Sun (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Takeda Pharmaceuticals U.s.a., Inc.. Retrieved from https://idiyas.com/company/takeda-pharmaceuticals-u-s-a

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…